Linjie Luo

6PUBLICATIONS
24CO-AUTHORS
Molecular targetsCancer geneticsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction.

Linjie Luo, Yan Wang, Tuyen Bui

|Dec 24, 2025
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts.

Xiao-Ting Jiang, Mei-Kuang Chen, Jiwang Lee

|Jan 05, 2023
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time.

Tuyen Duong Thanh Nguyen, Yan Wang, Tuyen N Bui

|Aug 26, 2022
Early Dietary Exposures Epigenetically Program Mammary Cancer Susceptibility through Igf1-Mediated Expansion of the Mammary Stem Cell Compartment.

Yuanning Zheng, Linjie Luo, Isabel U Lambertz

|Apr 18, 2022
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.

Linjie Luo, Khandan Keyomarsi

|Mar 31, 2022
Overexpression of IGF-1 During Early Development Expands the Number of Mammary Stem Cells and Primes them for Transformation.

Linjie Luo, Andres Santos, Kranti Konganti

Pageof 1

Frequent Collaborators

4 joint publications

Khandan Keyomarsi

3 joint publications

Yan Wang

3 joint publications

Kelly K Hunt

2 joint publications

Mei-Kuang Chen